Systematic adjudication of myocardial infarction end-points in an international clinical trial

Current Controlled Trials in Cardiovascular Medicine

Volumn 2, Issue 4, 2001, Pages 180-186

  Mahaffey, Kenneth W ^a   Harrington, Robert A ^a   Akkerhuis, Martijn ^b   Kleiman, Neal S ^c   Berdan, Lisa G ^a   Crenshaw, Brian S ^a   Tardiff, Barbara E ^a   Granger, Christopher B ^a   DeJong, Ingrid ^a   Bhapkar, Manju ^a   Widimsky, Petr ^d   Corbalon, Ramón ^e   Lee, Kerry L ^a   Deckers, Jaap W ^b   Simoons, Maarten L ^b   Topol, Eric J ^f   Califf, Robert M ^a  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c HOUSTON METHODIST HOSPITAL   (United States)

^d CHARLES UNIVERSITY   (Czech Republic)

^e PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE   (Chile)

^f LERNER RESEARCH INSTITUTE   (United States)

Author keywords

Acute coronary syndromes; Adjudication; Clinical events committee; Clinical trials; Myocardial infarction

Indexed keywords

EPTIFIBATIDE; FIBRINOGEN RECEPTOR; FIBRINOGEN RECEPTOR ANTAGONIST; HEART ENZYME; PLACEBO;

ARTICLE; CARDIOLOGY; CARDIOVASCULAR DISEASE; CLINICAL PRACTICE; CLINICAL PROTOCOL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ELECTROCARDIOGRAM; HEART INFARCTION; HUMAN; INFORMATION; INFORMATION PROCESSING; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MEDICAL SPECIALIST; MULTICENTER STUDY; ORGANIZATION; PROSPECTIVE STUDY; PUBLICATION; RANDOMIZED CONTROLLED TRIAL; STANDARDIZATION; SYNDROME; UNSTABLE ANGINA PECTORIS;

EID: 17944370493     PISSN: 14686708     EISSN: None     Source Type: Journal    
DOI: 10.1186/CVM-2-4-180     Document Type: Article

References (32)

1. A comparison of recombinant hirudin with heparin for the treatment of acute coronary syndromes
2. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty
3. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization
4. Collaborative overview of randomised trials of antiplatelet therapy I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients
5. Hirudin in acute myocardial infarction. Thrombolysis and Thrombin Inhibition in Myocardial Infarction (TIMI) 9B trial
6. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes without persistent ST-segment elevation: A randomized, placebo-controlled, clinical trial
7. A comparison of aspirin plus tirofiban with aspirin plus heparin for unstable angina
8. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction
9. Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention
10. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-IIb/IIIa blockade
11. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina
12. The FDA's critique of the anturane reinfarction trial
13. Classification of death in antiarrhythmia trials
14. Who should code cause of death in a clinical trial?
15. Reliability of death certificate diagnoses
16. Mode of death in chronic heart failure. A request and proposition for more accurate classification
17. Centralized systematic adjudication of clinical end-points in multicenter trials of acute coronary syndromes identifies patients at high risk for adverse clinical outcomes
18. Differences in endpoint identification by investigators versus independent review
19. Comparison of investigator and central events review of myocardial infarction rates as a means to improve events classification: Results from GUSTO-IIa
20. Surveillance and ascertainment of cardiovascular events. The Cardiovascular Health Study
21. Endpoint adjudication by clinical events committee can impact the statistical outcome of a clinical trial: Results from GUSTO-IIb
22. Disagreement between site investigators and clinical event committees is common and can affect trial results
23. The identification of MI in clinical trials is difficult and there is substantial difference between the assessment by site investigators and a clinical events committee: Results from PURSUIT
24. The impact of an end-point committee in a large multicentre, randomised, placebo-controlled clinical trial
25. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction
26. Randomised trial of intravenous streptokinase, oral aspirin, both or neither among 17, 187 case of suspected acute myocardial infarction: ISIS-2
27. Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction
28. Myonecrosis after revascularization procedures
29. Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non-Q-wave myocardial infarction: Results of the TIMI IIIB Trial
30. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the Survival And Ventricular Enlargement trial
31. A comparison of directional atherectomy with coronary angioplasty in patients with coronary artery disease
32. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty